Paradigm Biopharmaceuticals Ltd (PAR) - Cash Flow Conversion Efficiency

Latest as of December 2025: -3.276x

Based on the latest financial reports, Paradigm Biopharmaceuticals Ltd (PAR) has a cash flow conversion efficiency ratio of -3.276x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-19.65 Million ≈ $-13.90 Million USD) by net assets (AU$6.00 Million ≈ $4.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Paradigm Biopharmaceuticals Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Paradigm Biopharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Paradigm Biopharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Paradigm Biopharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Paradigm Biopharmaceuticals Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
DRTECH Corporation KQ:214680	-0.050x
Syntek Semiconductor Co Ltd TWO:5302	0.015x
Granite Point Mortgage Trust Inc NYSE:GPMT	-0.004x
Exasol AG XETRA:EXL	-0.444x
Dae Chang KO:012800	-0.035x
WI Co. Ltd. KQ:073570	-0.030x
Supercom Ltd NASDAQ:SPCB	-0.004x
MGB Bhd KLSE:7595	-0.059x

Annual Cash Flow Conversion Efficiency for Paradigm Biopharmaceuticals Ltd (2014–2025)

The table below shows the annual cash flow conversion efficiency of Paradigm Biopharmaceuticals Ltd from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see PAR market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$21.18 Million ≈ $14.99 Million	AU$-15.99 Million ≈ $-11.32 Million	-0.755x	+72.75%
2024-06-30	AU$23.81 Million ≈ $16.84 Million	AU$-65.94 Million ≈ $-46.66 Million	-2.770x	-229.06%
2023-06-30	AU$53.68 Million ≈ $37.98 Million	AU$-45.19 Million ≈ $-31.97 Million	-0.842x	-10.60%
2022-06-30	AU$42.31 Million ≈ $29.94 Million	AU$-32.21 Million ≈ $-22.79 Million	-0.761x	-70.56%
2021-06-30	AU$78.27 Million ≈ $55.38 Million	AU$-34.93 Million ≈ $-24.71 Million	-0.446x	-378.45%
2020-06-30	AU$108.18 Million ≈ $76.55 Million	AU$-10.09 Million ≈ $-7.14 Million	-0.093x	-21.34%
2019-06-30	AU$82.81 Million ≈ $58.59 Million	AU$-6.37 Million ≈ $-4.50 Million	-0.077x	+82.28%
2018-06-30	AU$13.86 Million ≈ $9.81 Million	AU$-6.01 Million ≈ $-4.25 Million	-0.434x	-29.92%
2017-06-30	AU$13.39 Million ≈ $9.47 Million	AU$-4.47 Million ≈ $-3.16 Million	-0.334x	-4.51%
2016-06-30	AU$11.23 Million ≈ $7.95 Million	AU$-3.59 Million ≈ $-2.54 Million	-0.319x	-284.01%
2015-06-30	AU$14.46 Million ≈ $10.23 Million	AU$-1.20 Million ≈ $-851.40K	-0.083x	-102.05%
2014-06-30	AU$-151.87K ≈ $-107.45K	AU$-617.72K ≈ $-437.08K	4.068x	--

About Paradigm Biopharmaceuticals Ltd

AU:PAR Australia Biotechnology

Market Cap

$63.20 Million

AU$89.33 Million AUD

Market Cap Rank

#21034 Global

#717 in Australia

Share Price

AU$0.17

Change (1 day)

-5.56%

52-Week Range

AU$0.14 - AU$0.47

All Time High

AU$4.35